美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Freenome, Inc.

14.64

-0.3200-2.14%

盤後：14.640.00000.00%19:30 EDT

成交量：52.34萬

成交額：762.79萬

市值：15.66億

市盈率：-212.17

高：15.53

開：14.96

低：14.25

收：14.96

52周最高：17.18

52周最低：9.95

股本：1.07億

流通股本：6,847.72萬

量比：0.88

換手率：0.76%

股息：- -

股息率：- -

每股收益(TTM):-0.0690

每股收益(LYR):-8.2800

淨資產收益率：--

總資產收益率：--

市淨率：-1.13

市盈率(LYR):-1.77

資料載入中...

總覽公司新聞資訊公告

FDA授予Freenome血檢技術「突破性器械認定」助力肺癌早篩全新突破

美國食品藥品監督管理局（FDA）批准了Freenome公司用於結直腸癌篩查的血液檢測

FDA批准Freenome的Simplescreen™ CRC血液篩查測試；雅培將在美國商業化

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/FRNM/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FRNM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FRNM\",,,,,undefined,":{"symbol":"FRNM","market":"US","secType":"STK","nameCN":"Freenome, Inc.","latestPrice":14.64,"timestamp":1789502400000,"preClose":14.96,"halted":0,"volume":523404,"hourTrading":{"tag":"盘后","latestPrice":14.64,"preClose":14.64,"latestTime":"19:30 EDT","volume":711,"amount":10409.04,"timestamp":1789515005068,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.021390374331550818,"floatShares":68477200,"shares":107000000,"eps":-0.069,"marketStatus":"未開盤","change":-0.32,"latestTime":"09-15 16:00:00 EDT","open":14.96,"high":15.525,"low":14.25,"amount":7627851.485478001,"amplitude":0.085227,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.069,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"listingDate":1718164800000,"exchange":"NASDAQ","adjPreClose":14.96,"preHourTrading":{"tag":"盘前","latestPrice":16.15,"preClose":14.96,"latestTime":"08:56 EDT","volume":9,"amount":145.35,"timestamp":1789476961559,"change":1.19,"changeRate":0.079545,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":14.64,"preClose":14.64,"latestTime":"19:30 EDT","volume":711,"amount":10409.04,"timestamp":1789515005068,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.877783},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FRNM\",,,,,undefined,":{"symbol":"FRNM","floatShares":68477200,"roa":"--","roe":"--","lyrEps":-8.279999,"volumeRatio":0.877783,"shares":107000000,"dividePrice":0,"high":15.525,"amplitude":0.085227,"preClose":14.96,"low":14.25,"week52Low":9.95,"pbRate":"-1.13","psRate":"44.24","week52High":17.175,"institutionHeld":0,"latestPrice":14.64,"eps":-0.069,"divideRate":0,"volume":523404,"delay":0,"ttmEps":-0.069,"open":14.96,"prevYearClose":13.03,"prevWeekClose":14.37,"prevMonthClose":14.79,"prevQuarterClose":10.88,"fiveDayClose":15.99,"twentyDayClose":13,"sixtyDayClose":11.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FRNM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-15","symbol":"FRNM","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1784088000000,"reportTimeType":"pre","actualEps":-0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FRNM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FRNM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":3,"updateTime":1787284800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FRNM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FRNM","date":"2026-09-14","current":-212.173913,"percent":0.363636,"low":-7.716322,"twenty":-6.799708,"median":-6.335146,"eighty":-5.563945,"high":-5.010259,"avg":-6.262503,"sd":0.708157,"marketCap":1544010717},"quantilePoints":[{"date":"2026-07-31","current":-5.010259,"twenty":-5.523823,"median":-5.223408,"eighty":-5.031323,"marketCap":1127448482},{"date":"2026-08-07","current":-5.471664,"twenty":-5.549902,"median":-5.471664,"eighty":-5.259016,"marketCap":1231277572},{"date":"2026-08-14","current":-5.822733,"twenty":-5.804678,"median":-5.556923,"eighty":-5.443578,"marketCap":1310277966},{"date":"2026-08-21","current":-6.775635,"twenty":-6.21894,"median":-5.707382,"eighty":-5.471664,"marketCap":1524707608},{"date":"2026-08-28","current":-6.364824,"twenty":-6.405917,"median":-5.810195,"eighty":-5.471664,"marketCap":1497808587},{"date":"2026-09-04","current":-7.716322,"twenty":-6.752923,"median":-6.018329,"eighty":-5.501756,"marketCap":1815851156},{"date":"2026-09-11","current":-6.752923,"twenty":-6.811745,"median":-6.305468,"eighty":-5.549902,"marketCap":1589138379},{"date":"2026-09-14","current":-6.561157,"twenty":-6.799708,"median":-6.335146,"eighty":-5.563945,"marketCap":1544010717}],"updateTime":1789543824659},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FRNM\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1195738387","title":"FDA授予Freenome血檢技術「突破性器械認定」 助力肺癌早篩全新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1195738387","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195738387?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:02","pubTimestamp":1786539720,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）正式授予Freenome公司基于血液的Simplescreen™肺癌筛查检测工具“突破性器械认定”。这一认定，标志着该无创检验技术有望在降低肺癌死亡率方面扮演关键角色。简而言之，它意味着FDA将加速审查这款非侵入性、基于液体活检的创新产品，以更快地将其推向市场，惠及更多高风险人群。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048086","title":"美國食品藥品監督管理局（FDA）批准了Freenome公司用於結直腸癌篩查的血液檢測","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048086","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048086?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 21:13","pubTimestamp":1785157998,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局批准了Freenome公司用于结直肠癌筛查的血液检测路透7月27日-两家公司周一表示，美国食品药品监督管理局已批准Freenome公司针对年龄较大的成年人的FRNM.O血液结直肠癌筛查检测，为合作伙伴雅培公司今秋在美国推出该产品铺平了道路。美国食品药品监督管理局批准该检测适用于45岁及以上中风险成年人，这使Freenome拥有了其首个商业化产品。根据2025年签署的商业化协议，Freenome将从雅培公司获得与此次批准相关的1亿美元里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4T43T12N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0170899867.USD","LU2133065610.SGD","IE00BJJMRZ35.SGD","GNMX","PTH","BK4535","LU0266013472.USD","BK4585","PJP","BK4588","LU0882574055.USD","LU2237957902.USD","LU0868494617.USD","BK4551","GNOM","LU1061106388.HKD","BK4568","FFOX","LU0234572021.USD","LU1989763690.USD","LU2112291526.USD","SG9999002232.USD","LU0122379950.USD","FRNM","LU0432979614.USD","SG9999004303.SGD","LU1989763427.SGD","LU1721429741.USD","LU1914381329.SGD","IE0002141913.USD","GDOC","LFSC","LU0320765992.SGD","LU0889565916.HKD","HELX","LU2237957811.SGD","SGXZ23171101.USD","TMED","IHI","SG9999002224.SGD","LU0058720904.USD","LU2211815571.USD","BK4082","IE00B2B36J28.USD","ABT","BK4566","LU2468319806.SGD","EKG","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185531891","title":"FDA批准Freenome的Simplescreen™ CRC血液篩查測試；雅培將在美國商業化","url":"https://stock-news.laohu8.com/highlight/detail?id=1185531891","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185531891?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 20:01","pubTimestamp":1785153709,"startTime":"0","endTime":"0","summary":"FDA已正式批准Freenome公司研发的Simplescreen™ CRC血液筛查测试。这款基于血液样本的结直肠癌筛查工具，将被授权给雅培（Abbott）在美国市场进行商业化推广。这一决定标志着非侵入性癌症检测领域迈出了关键一步，为患者提供了更便捷的筛查选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRNM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}